Evidence map›Paper›PMID 24434212›Full record

ArticleCancer cell2014

Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

Jens G Lohr, Petar Stojanov, Scott L Carter, Peter Cruz-Gordillo, Michael S Lawrence, Daniel Auclair, Carrie Sougnez, Birgit Knoechel, Joshua Gould, Gordon Saksena and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 636 papers.

0numbers the graph read from it
0cells of the map it votes in
636citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

636 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Inferring and summarizing tumor phylogenies from bulk DNA data.Algorithms for molecular biology : AMB · 2026
    Article
  20. Review

576 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jens G LohrBroad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
Petar StojanovBroad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
Scott L CarterBroad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA.
Peter Cruz-GordilloBroad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA.
Michael S LawrenceBroad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA.
Daniel AuclairBroad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA.
Carrie SougnezBroad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA.
Birgit KnoechelBroad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Boston Children's Hospital, 350 Longwood Avenue, Boston, MA 02115, USA.
Joshua GouldBroad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA.
Gordon SaksenaBroad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA.
Kristian CibulskisBroad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA.
Aaron McKennaBroad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA.
Michael A ChapmanCambridge Institute for Medical Research, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0XY, UK.
Ravid StraussmanBroad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA.
Joan LevyThe Multiple Myeloma Research Foundation, 383 Main Avenue, Fifth Floor, Norwalk, CT 06581, USA.
Louise M PerkinsThe Multiple Myeloma Research Foundation, 383 Main Avenue, Fifth Floor, Norwalk, CT 06581, USA.
Jonathan J KeatsTranslational Genomics Research Institute (TGen), 445 N. Fifth Street, Phoenix, AZ 85004, USA.
Steven E SchumacherBroad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
Mara RosenbergBroad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA.
Multiple Myeloma Research Consortium
Gad GetzBroad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA; Massachusetts General Hospital Cancer Center and Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Todd R GolubBroad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. Electronic address: golub@broadinstitute.org.

Funding

Trageting the Multiple Myeloma EpigenomeP50CA100707 · NCI · DANA-FARBER CANCER INSTITUTE · PI ANDERSON, KENNETH C., MUNSHI, NIKHIL C. · 2003 to 2023
$45.0M
Signatures of Kinase Activation in Cancer (MIT consortium)U54CA112962 · NCI · DANA-FARBER CANCER INSTITUTE · PI GOLUB, TODD R. · 2004 to 2014
$24.2M
Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
Howard Hughes Medical InstituteNCI NIH HHS 5P50CA100707-09NCI NIH HHS P50 CA100707NCI NIH HHS T32 CA009172NCI NIH HHS U54 CA112962World Health Organization 001
6 · The paper itself

Abstract

We performed massively parallel sequencing of paired tumor/normal samples from 203 multiple myeloma (MM) patients and identified significantly mutated genes and copy number alterations and discovered putative tumor suppressor genes by determining homozygous deletions and loss of heterozygosity. We observed frequent mutations in KRAS (particularly in previously treated patients), NRAS, BRAF, FAM46C, TP53, and DIS3 (particularly in nonhyperdiploid MM). Mutations were often present in subclonal populations, and multiple mutations within the same pathway (e.g., KRAS, NRAS, and BRAF) were observed in the same patient. In vitro modeling predicts only partial treatment efficacy of targeting subclonal mutations, and even growth promotion of nonmutated subclones in some cases. These results emphasize the importance of heterogeneity analysis for treatment decisions.

Indexed as

Genetic HeterogeneityBlotting, WesternGene DosageHumansMultiple MyelomaMutationSequence Analysis, DNA

Identifiers

PMID24434212
PMCPMC4241387

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.